Guangzhou Improve Med Instrument
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising urine, feces, and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The… Read more
Guangzhou Improve Med Instrument (300030) - Net Assets
Latest net assets as of September 2025: CN¥664.29 Million CNY
Based on the latest financial reports, Guangzhou Improve Med Instrument (300030) has net assets worth CN¥664.29 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.08 Billion) and total liabilities (CN¥415.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥664.29 Million |
| % of Total Assets | 61.52% |
| Annual Growth Rate | 21.5% |
| 5-Year Change | -35.79% |
| 10-Year Change | -30.8% |
| Growth Volatility | 145.37 |
Guangzhou Improve Med Instrument - Net Assets Trend (2006–2024)
This chart illustrates how Guangzhou Improve Med Instrument's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangzhou Improve Med Instrument (2006–2024)
The table below shows the annual net assets of Guangzhou Improve Med Instrument from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥643.86 Million | -15.54% |
| 2023-12-31 | CN¥762.33 Million | -7.10% |
| 2022-12-31 | CN¥820.61 Million | -20.36% |
| 2021-12-31 | CN¥1.03 Billion | +2.75% |
| 2020-12-31 | CN¥1.00 Billion | +19.63% |
| 2019-12-31 | CN¥838.26 Million | +2.79% |
| 2018-12-31 | CN¥815.47 Million | -15.38% |
| 2017-12-31 | CN¥963.72 Million | +1.00% |
| 2016-12-31 | CN¥954.18 Million | +2.55% |
| 2015-12-31 | CN¥930.46 Million | +18.98% |
| 2014-12-31 | CN¥782.00 Million | +1.20% |
| 2013-12-31 | CN¥772.70 Million | +12.32% |
| 2012-12-31 | CN¥687.93 Million | +6.12% |
| 2011-12-31 | CN¥648.25 Million | +9.40% |
| 2010-12-31 | CN¥592.55 Million | +5.15% |
| 2009-12-31 | CN¥563.53 Million | +615.80% |
| 2008-12-31 | CN¥78.73 Million | +35.12% |
| 2007-12-31 | CN¥58.27 Million | +201.39% |
| 2006-12-31 | CN¥19.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Improve Med Instrument's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1907.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥309.19 Million | 50.96% |
| Other Comprehensive Income | CN¥53.87 Million | 8.88% |
| Other Components | CN¥394.47 Million | 65.02% |
| Total Equity | CN¥606.73 Million | 100.00% |
Guangzhou Improve Med Instrument Competitors by Market Cap
The table below lists competitors of Guangzhou Improve Med Instrument ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kaimei Electronic Corp
TW:2375
|
$234.76 Million |
|
Msscorps Co Ltd
TW:6830
|
$234.76 Million |
|
LB Foster Company
NASDAQ:FSTR
|
$234.93 Million |
|
Appen Ltd
AU:APX
|
$234.95 Million |
|
Wirtualna Polska Holding SA
WAR:WPL
|
$234.68 Million |
|
Zhang Xiaoquan Inc.
SHE:301055
|
$234.62 Million |
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
$234.56 Million |
|
Guilin Tourism Corp Ltd
SHE:000978
|
$234.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Improve Med Instrument's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 723,084,475 to 606,734,458, a change of -116,350,017 (-16.1%).
- Net loss of 117,903,784 reduced equity.
- Dividend payments of 11,966,649 reduced retained earnings.
- Other comprehensive income increased equity by 53,869,765.
- Other factors decreased equity by 40,349,349.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-117.90 Million | -19.43% |
| Dividends Paid | CN¥11.97 Million | -1.97% |
| Other Comprehensive Income | CN¥53.87 Million | +8.88% |
| Other Changes | CN¥-40.35 Million | -6.65% |
| Total Change | CN¥- | -16.09% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Improve Med Instrument's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 77.36x to 4.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.11 | CN¥8.22 | x |
| 2007-12-31 | CN¥0.32 | CN¥8.22 | x |
| 2008-12-31 | CN¥0.40 | CN¥8.22 | x |
| 2009-12-31 | CN¥2.67 | CN¥8.22 | x |
| 2010-12-31 | CN¥2.04 | CN¥8.22 | x |
| 2011-12-31 | CN¥2.11 | CN¥8.22 | x |
| 2012-12-31 | CN¥2.16 | CN¥8.22 | x |
| 2013-12-31 | CN¥2.37 | CN¥8.22 | x |
| 2014-12-31 | CN¥2.48 | CN¥8.22 | x |
| 2015-12-31 | CN¥3.00 | CN¥8.22 | x |
| 2016-12-31 | CN¥3.10 | CN¥8.22 | x |
| 2017-12-31 | CN¥3.42 | CN¥8.22 | x |
| 2018-12-31 | CN¥2.61 | CN¥8.22 | x |
| 2019-12-31 | CN¥2.71 | CN¥8.22 | x |
| 2020-12-31 | CN¥3.24 | CN¥8.22 | x |
| 2021-12-31 | CN¥3.23 | CN¥8.22 | x |
| 2022-12-31 | CN¥2.54 | CN¥8.22 | x |
| 2023-12-31 | CN¥2.29 | CN¥8.22 | x |
| 2024-12-31 | CN¥1.96 | CN¥8.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Improve Med Instrument utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.28%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 2.05x
- Recent ROE (-19.43%) is below the historical average (4.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 43.16% | 18.91% | 1.10x | 2.07x | CN¥6.41 Million |
| 2007 | 22.64% | 18.24% | 0.98x | 1.27x | CN¥7.36 Million |
| 2008 | 25.99% | 19.78% | 0.73x | 1.80x | CN¥12.59 Million |
| 2009 | 4.77% | 19.11% | 0.21x | 1.17x | CN¥-29.45 Million |
| 2010 | 4.90% | 17.50% | 0.25x | 1.10x | CN¥-30.23 Million |
| 2011 | 5.75% | 14.29% | 0.35x | 1.15x | CN¥-26.41 Million |
| 2012 | 5.80% | 12.32% | 0.40x | 1.19x | CN¥-27.13 Million |
| 2013 | 6.74% | 11.62% | 0.45x | 1.29x | CN¥-22.31 Million |
| 2014 | 7.27% | 11.49% | 0.45x | 1.40x | CN¥-19.94 Million |
| 2015 | 4.33% | 7.30% | 0.38x | 1.56x | CN¥-52.23 Million |
| 2016 | 3.23% | 5.89% | 0.35x | 1.56x | CN¥-63.96 Million |
| 2017 | 1.17% | 2.03% | 0.31x | 1.83x | CN¥-84.33 Million |
| 2018 | -16.87% | -24.87% | 0.36x | 1.86x | CN¥-217.88 Million |
| 2019 | 3.11% | 4.53% | 0.38x | 1.80x | CN¥-57.57 Million |
| 2020 | 16.26% | 17.68% | 0.53x | 1.75x | CN¥62.54 Million |
| 2021 | 1.86% | 2.32% | 0.44x | 1.82x | CN¥-81.45 Million |
| 2022 | -24.64% | -27.19% | 0.46x | 1.99x | CN¥-271.73 Million |
| 2023 | -8.74% | -9.80% | 0.45x | 1.97x | CN¥-135.51 Million |
| 2024 | -19.43% | -20.28% | 0.47x | 2.05x | CN¥-178.58 Million |
Industry Comparison
This section compares Guangzhou Improve Med Instrument's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,430,306,004
- Average return on equity (ROE) among peers: 13.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Improve Med Instrument (300030) | CN¥664.29 Million | 43.16% | 0.63x | $234.74 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |